A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,220

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

Mometasone furoate

DRUG

Nasonex Nasal Spray

DRUG

Placebo nasal spray

Trial Locations (1)

San Antonio